Chugai Pharmaceutical Co., Ltd. (CHGCY)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Chugai Pharmaceutical Co., Ltd. (CHGCY) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Die Aktie erzielt 55/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 16. März 2026Chugai Pharmaceutical Co., Ltd. (CHGCY) Gesundheitswesen & Pipeline-Uebersicht
Chugai Pharmaceutical Co., Ltd., a subsidiary of Roche, develops and markets innovative pharmaceuticals, primarily in oncology, osteoporosis, renal diseases, and neurology. With a strong focus on research and strategic alliances, Chugai operates globally, leveraging its robust product portfolio and a high profit margin of 34.5% within the competitive pharmaceutical landscape.
Investmentthese
Chugai Pharmaceutical presents a compelling investment case based on its robust product portfolio, strong profit margins, and strategic alignment with Roche. With a P/E ratio of 34.57 and a dividend yield of 2.98%, Chugai demonstrates financial stability and shareholder value. The company’s focus on key therapeutic areas like oncology and neurology, coupled with its pipeline of development product candidates, positions it for sustained growth. Its gross margin of 71.1% indicates efficient operations and strong pricing power. Key growth catalysts include the expansion of its oncology product line and successful clinical trials for new drug candidates. However, potential risks include regulatory hurdles and competition from other pharmaceutical giants. Investors should monitor the progress of its pipeline and the impact of currency fluctuations on its ADR.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market Cap of $95.98B reflects its significant presence in the pharmaceutical industry.
- P/E Ratio of 34.57 indicates investor expectations of future earnings growth.
- Profit Margin of 34.5% showcases strong operational efficiency and profitability.
- Gross Margin of 71.1% demonstrates effective cost management and pricing power.
- Dividend Yield of 2.98% provides a steady income stream for investors.
Wettbewerber & Vergleichsunternehmen
Staerken
- Strong research and development capabilities
- Strategic alliance with Roche
- Diverse product portfolio
- High profit margin
Schwaechen
- Reliance on key products for revenue
- Exposure to regulatory risks
- Competition from larger pharmaceutical companies
- Currency fluctuation risks
Katalysatoren
- Upcoming: Clinical trial results for new drug candidates in oncology and autoimmune diseases expected in Q4 2026.
- Ongoing: Expansion of existing product lines into new geographic markets, particularly in Asia and Latin America.
- Ongoing: Strategic partnerships with biotechnology companies to enhance research and development capabilities.
- Upcoming: Regulatory approvals for new drug applications in key markets expected in H1 2027.
Risiken
- Potential: Patent expirations on key products could lead to generic competition and reduced revenue.
- Ongoing: Regulatory hurdles and delays in drug approvals could impact the company's growth prospects.
- Potential: Increased competition from other pharmaceutical companies could erode market share.
- Ongoing: Currency fluctuations could negatively impact the value of the ADR and the company's financial results.
- Potential: Product liability claims and litigation could result in significant financial losses.
Wachstumschancen
- Expansion of Oncology Product Line: Chugai's strong presence in oncology, with key products like Avastin and Tecentriq, provides a significant growth opportunity. The global oncology market is projected to reach $286.6 billion by 2028, driven by increasing cancer incidence and advancements in targeted therapies. Chugai can leverage its research capabilities and strategic alliances with Roche to develop and market new oncology drugs, capturing a larger share of this expanding market. This includes ongoing clinical trials and regulatory approvals for novel cancer treatments.
- Development of Novel Therapies for Autoimmune Diseases: The market for autoimmune disease therapies is growing, driven by increasing diagnosis rates and the development of more effective treatments. Chugai has several product candidates in development targeting autoimmune diseases. Successful clinical trials and regulatory approvals could lead to significant revenue growth. The global autoimmune disease treatment market is expected to reach $150 billion by 2027, presenting a substantial opportunity for Chugai.
- Strategic Partnerships and Collaborations: Chugai's strategic alliances with Roche Group and collaborations with academia provide access to cutting-edge research and development capabilities. These partnerships can accelerate the development of new drugs and expand Chugai's market reach. By leveraging these collaborations, Chugai can enhance its innovation pipeline and maintain a competitive edge in the pharmaceutical industry. The timeline for realizing benefits from these partnerships depends on the progress of specific research projects and regulatory approvals.
- Geographic Expansion into Emerging Markets: Expanding into emerging markets, particularly in Asia and Latin America, represents a significant growth opportunity for Chugai. These markets are experiencing rapid economic growth and increasing healthcare spending. By establishing a presence in these regions, Chugai can tap into new customer bases and diversify its revenue streams. This expansion requires careful market analysis, regulatory compliance, and strategic partnerships with local distributors. The timeline for successful geographic expansion varies depending on the specific market and regulatory environment.
- Advancements in Personalized Medicine: Chugai can capitalize on the growing trend of personalized medicine by developing targeted therapies based on individual patient characteristics. This approach involves using genetic and biomarker data to identify patients who are most likely to respond to specific treatments. By investing in personalized medicine research and development, Chugai can improve treatment outcomes and differentiate itself from competitors. The market for personalized medicine is expected to reach $3.2 trillion by 2025, presenting a substantial opportunity for Chugai.
Chancen
- Expansion into emerging markets
- Development of novel therapies
- Advancements in personalized medicine
- Strategic acquisitions
Risiken
- Patent expirations
- Generic competition
- Pricing pressures
- Unfavorable regulatory changes
Wettbewerbsvorteile
- Strong research and development capabilities
- Strategic alliance with Roche
- Patented pharmaceutical products
- Established brand reputation
Ueber CHGCY
Founded in 1925 and headquartered in Tokyo, Japan, Chugai Pharmaceutical Co., Ltd. has evolved into a prominent research-based pharmaceutical company with a global presence. As a subsidiary of Roche Holding Ltd, Chugai leverages strategic alliances and innovative research to develop, manufacture, and market pharmaceutical products. The company's diverse portfolio addresses critical therapeutic areas, including oncology, osteoporosis, renal diseases, and neurology. Key oncology products include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. For osteoporosis, Chugai offers Actemra, Edirol, and Bonviva. Renal disease treatments include Mircera and Oxarol, while neurology and other disease areas are addressed with Hemlibra, CellCept, and Enspryng. Chugai's commitment to research and development is evident in its pipeline of product candidates targeting oncology, bone and joint diseases, autoimmune diseases, renal diseases, and neurology. The company's strategic alliances, particularly with the Roche Group, and collaborations with academia enhance its research capabilities and market reach. Chugai operates both in Japan and internationally, exporting its pharmaceutical products to various markets.
Was das Unternehmen tut
- Researches and develops pharmaceutical products.
- Manufactures and sells pharmaceutical products.
- Imports and exports pharmaceutical products.
- Focuses on therapeutic areas such as oncology, osteoporosis, renal diseases, and neurology.
- Engages in strategic alliances with Roche Group.
- Collaborates with academia for research and development.
- Markets products internationally.
Geschaeftsmodell
- Develops and patents innovative pharmaceutical products.
- Generates revenue through the sale of prescription drugs.
- Invests heavily in research and development to create new products.
- Partners with Roche for global distribution and marketing.
Branchenkontext
Chugai Pharmaceutical operates within the highly competitive global pharmaceutical industry, characterized by intense research and development, stringent regulatory requirements, and evolving market dynamics. The industry is experiencing growth driven by an aging population, increasing prevalence of chronic diseases, and technological advancements in drug discovery. Chugai's focus on specialized therapeutic areas like oncology and neurology positions it favorably within this landscape. Competitors include major pharmaceutical companies such as CMXHF (Cemex Holdings Philippines), DSKYF (Daiso Sangyo Co Ltd), DSNKY (Daiichi Sankyo Co Ltd), GLAXF (GlaxoSmithKline PLC), and HOCPY (Hoya Corp).
Wichtige Kunden
- Hospitals and clinics
- Pharmacies
- Healthcare providers
- Patients
Finanzdaten
Chart & Info
Chugai Pharmaceutical Co., Ltd. (CHGCY) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Lows On Tuesday
· 24. März 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· 24. März 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· 11. Feb. 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· 4. Feb. 2020
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CHGCY.
Kursziele
Wall-Street-Kurszielanalyse fuer CHGCY.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von CHGCY auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Osamu Okuda
CEO
Osamu Okuda serves as the CEO of Chugai Pharmaceutical Co., Ltd. His career spans several decades in the pharmaceutical industry, with a focus on strategic planning, research and development, and global market expansion. He has held various leadership positions within Chugai, contributing to the company's growth and innovation. Okuda's expertise lies in navigating the complex regulatory landscape and fostering strategic alliances to drive pharmaceutical advancements. His educational background includes advanced studies in pharmaceutical sciences.
Erfolgsbilanz: Under Osamu Okuda's leadership, Chugai has strengthened its strategic alliance with Roche, expanded its oncology product line, and advanced its pipeline of development product candidates. He has overseen the successful launch of several key products, contributing to the company's revenue growth and market share. Okuda has also focused on improving operational efficiency and fostering a culture of innovation within the organization.
Chugai Pharmaceutical Co., Ltd. ADR-Informationen Nicht gesponsert
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company, allowing U.S. investors to trade the stock on American exchanges. CHGCY is traded as an unsponsored Level 1 ADR. This means that Chugai Pharmaceutical does not directly participate in facilitating the trading of its shares in the U.S., and the ADR is traded over-the-counter.
- Heimatmarkt-Ticker: Tokyo Stock Exchange, Japan
- ADR-Stufe: 1
- ADR-Verhaeltnis: 1:1
- Heimatmarkt-Ticker: CHGC
CHGCY OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing requirements. Trading on the OTC Other tier carries higher risks compared to trading on major exchanges like the NYSE or NASDAQ, due to the lack of regulatory oversight and transparency. These securities are often considered speculative and may be subject to significant price volatility.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure
- Low trading volume
- Price volatility
- Lack of regulatory oversight
- Potential for fraud or manipulation
- Verify the company's registration and legal status.
- Review available financial reports and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC securities.
- Consult with a financial advisor.
- Monitor news and developments related to the company.
- Subsidiary of Roche Holding Ltd
- Established pharmaceutical company with a long history
- Presence in key therapeutic areas
- Strategic alliances and collaborations
CHGCY Healthcare Aktien-FAQ
What are the key factors to evaluate for CHGCY?
Chugai Pharmaceutical Co., Ltd. (CHGCY) currently holds an AI score of 55/100, indicating moderate score. Key strength: Strong research and development capabilities. Primary risk to monitor: Potential: Patent expirations on key products could lead to generic competition and reduced revenue.. This is not financial advice.
How frequently does CHGCY data refresh on this page?
CHGCY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CHGCY's recent stock price performance?
Recent price movement in Chugai Pharmaceutical Co., Ltd. (CHGCY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong research and development capabilities. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CHGCY overvalued or undervalued right now?
Determining whether Chugai Pharmaceutical Co., Ltd. (CHGCY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CHGCY?
Before investing in Chugai Pharmaceutical Co., Ltd. (CHGCY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CHGCY to a portfolio?
Potential reasons to consider Chugai Pharmaceutical Co., Ltd. (CHGCY) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Strong research and development capabilities. Additionally: Strategic alliance with Roche. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of CHGCY?
Yes, most major brokerages offer fractional shares of Chugai Pharmaceutical Co., Ltd. (CHGCY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CHGCY's earnings and financial reports?
Chugai Pharmaceutical Co., Ltd. (CHGCY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CHGCY earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and may be subject to change.
- AI analysis is pending for CHGCY.